Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Rasche

Showing results (61-70 of 170) with videos related to

Pageof 17
Sort By:
European Journal of Haematology|January 11, 2020
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphomaXiang Zhou, Maximilian Johannes Steinhardt, Johannes Düll, et al.
Microbiology Spectrum|December 13, 2023
Lymphocyte and neutrophil count combined with intestinal bacteria abundance predict the severity of COVID-19Liuying Chen, Zhongwei Yin, Dan Zhou, et al.
International Journal of Immunopathology and Pharmacology|December 23, 2020
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myelomaMaximilian Johannes Steinhardt, Xiang Zhou, Franziska Krummenast, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2026
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple MyelomaPaula Rodríguez-Otero, Philippe Moreau, Maria Victoria Mateos, et al.
European Journal of Radiology|August 26, 2022
Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by <sup>18</sup>F-FDG and <sup>11</sup>C-methionine PET/CTAnke Heidemeier, Wiebke Schloetelburg, Annette Thurner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2016
A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary InvolvementLeo Rasche, Emmanuelle Menoret, Valentina Dubljevic, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Clinical and Experimental Medicine|October 7, 2023
Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligenceMax Bittrich, Regina Hetterich, Antonio G Solimando, et al.
Blood Cancer Discovery|September 4, 2025
Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapiesMarios Papadimitriou, Sungwoo Ahn, Benjamin T Diamond, et al.
Cancer Medicine|December 8, 2025
Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose MelphalanAnna Fleischer, Magdalena Roll, Jan H Frenking, et al.
Pageof 17

Showing results (61-70 of 170) with videos related to

Sort By:
Pageof 17
European Journal of Haematology|January 11, 2020
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphomaXiang Zhou, Maximilian Johannes Steinhardt, Johannes Düll, et al.
Microbiology Spectrum|December 13, 2023
Lymphocyte and neutrophil count combined with intestinal bacteria abundance predict the severity of COVID-19Liuying Chen, Zhongwei Yin, Dan Zhou, et al.
International Journal of Immunopathology and Pharmacology|December 23, 2020
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myelomaMaximilian Johannes Steinhardt, Xiang Zhou, Franziska Krummenast, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2026
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple MyelomaPaula Rodríguez-Otero, Philippe Moreau, Maria Victoria Mateos, et al.
European Journal of Radiology|August 26, 2022
Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by <sup>18</sup>F-FDG and <sup>11</sup>C-methionine PET/CTAnke Heidemeier, Wiebke Schloetelburg, Annette Thurner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2016
A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary InvolvementLeo Rasche, Emmanuelle Menoret, Valentina Dubljevic, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
Clinical and Experimental Medicine|October 7, 2023
Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligenceMax Bittrich, Regina Hetterich, Antonio G Solimando, et al.
Blood Cancer Discovery|September 4, 2025
Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapiesMarios Papadimitriou, Sungwoo Ahn, Benjamin T Diamond, et al.
Cancer Medicine|December 8, 2025
Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose MelphalanAnna Fleischer, Magdalena Roll, Jan H Frenking, et al.
Pageof 17